DCF Advisers, LLC - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 281 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2022. The put-call ratio across all filers is 0.83 and the average weighting 0.2%.

Quarter-by-quarter ownership
DCF Advisers, LLC ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q3 2023$5,581,808
-17.7%
107,1570.0%3.04%
-15.2%
Q2 2023$6,785,181
+5.7%
107,157
-9.6%
3.58%
-8.8%
Q1 2023$6,422,190
-22.3%
118,600
-24.1%
3.93%
-29.7%
Q4 2022$8,268,750
+7.1%
156,250
-5.9%
5.59%
+12.0%
Q3 2022$7,724,000
-34.5%
165,999
-19.6%
4.99%
-28.9%
Q2 2022$11,792,000
-19.2%
206,588
-13.4%
7.02%
+9.9%
Q1 2022$14,594,000
-22.3%
238,500
-33.6%
6.39%
-16.1%
Q4 2021$18,790,000
+33.0%
359,000
-5.3%
7.62%
+22.2%
Q3 2021$14,129,000
-7.7%
379,000
+1.1%
6.24%
+15.0%
Q2 2021$15,308,000
+6.3%
375,000
-11.7%
5.42%
-13.4%
Q1 2021$14,403,000
+6.7%
424,5000.0%6.26%
+12.4%
Q4 2020$13,499,000
+23.2%
424,500
-0.6%
5.57%
-0.6%
Q3 2020$10,957,000
+0.3%
427,000
+0.4%
5.60%
-8.3%
Q2 2020$10,923,000
+64.3%
425,500
-1.6%
6.11%
+40.5%
Q1 2020$6,648,000
-58.6%
432,500
-7.6%
4.35%
-57.2%
Q4 2019$16,060,000468,07310.17%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q4 2022
NameSharesValueWeighting ↓
Sarissa Capital Management LP 640,000$25,626,0006.33%
Redmile Group, LLC 1,322,592$52,957,0004.01%
SENZAR ASSET MANAGEMENT, LLC 556,224$22,271,209,0003.24%
RA Capital Management 314,349$12,587,0001.81%
WALL STREET ASSOCIATES 205,657$8,235,0001.58%
Parametrica Management Ltd 5,400$216,0001.36%
Rhenman & Partners Asset Management AB 165,000$6,607,0001.05%
EAM Investors, LLC 95,168$3,811,0000.60%
Rock Springs Capital Management LP 180,000$7,207,0000.58%
WASATCH ADVISORS LP 1,085,973$43,482,0000.58%
View complete list of INTRA CELLULAR THERAPIES INC shareholders